醋酸亮脯利特对控制下卵巢过度刺激和宫内人工受精的妇女黄体期功能的影响  

Impact of leuprolide acetate on luteal phase function in women undergoing controlled ovarian hyperstimulation and intrauterine insemination

作　　者：Duffy D.A. Manzi D. Benadiva C. J.Nulsen 张旸 

机构地区：[1]Center for Advanced Reproductive Services,Dowling South Building, 263 Farmington Avenue, Farmington, CT 06030- 6224, United States,Dr.

出　　处：《世界核心医学期刊文摘（妇产科学分册）》2006年第6期17-18,共2页Core Journal in Obstetrics/Gynecology

摘　　要：Objective: To determine if the combination of leuprolide acetate (LA) and human menopausal gonadotropin (hMG) results in luteal phase dysfunction. Design: A prospective, randomized clinical trial. Setting: A tertiary care university fertility center. Patient(s): One hundred thirty- five couples with various etiologies of infertility. Intervention(s): Patients were prospectively randomized to receive either hMG and intrauterine insemination (IUI) or luteal phase down- regulation with LA, hMG, and IUI. Main Outcome Measure(s): Serum luteal phase progesterone (P) and luteal phase estradiol (E2) were obtained 9 days after hCG administration. Twenty- four- hour urinary P and luteinizing hormone (LH) were analyzed 9 days after human chorionic gonadotropin (hCG). Endometrial biopsies were performed 11 days after hCG and evaluated for luteal phase defects (LPD) using Noyes’ criteria. Result(s): No significant differences in the incidence of LPD (11.9% vs. 13.9% ), cycle fecundity (16.6% vs. 16.3% ), or luteal phase hormone profiles were observed between the groups receiving and not receiving LA. A significant difference in E2 levels (on the day of hCG administration) between cycles with a luteal phase defect (967 ± 106 pg/mL) and without a luteal phase defect (1,422 ± 83 pg/mL) was observed (P < .05). Conclusion(s): Pituitary down- regulation with LA combined with hMG did not result in luteal phase dysfunction. The E2 levels on the day of hCG administration in both groups were lower in women with documented luteal phase defects.Objective： To determine if the combination of leuprolide acetate （LA） and human menopausal gonadotropin （hMG） results in luteal phase dysfunction. Design： A prospective, randomized clinical trial. Setting： A tertiary care university fertility center. Patient（s）： One hundred thirty-five couples with various etiologies of infertility. Intervention（s）： Patients were prospectively randomized to receive either hMG and intrauterine insemination （IUI） or luteal phase down-regulation with LA, hMG, and IUI. Main Outcome Measure（s）： Serum luteal phase progesterone （P） and luteal phase estradiol （E2） were obtained 9 days after hCG administration. Twenty-four-hour urinary P and luteinizing hormone （LH） were analyzed 9 days after human chorionic gonadotropin （hCG）. Endometrial biopsies were performed 11 days after hCG and evaluated for luteal phase defects （LPD） using Noyes＇ criteria. Result（s）： No significant differences in the incidence of LPD （11.9% vs. 13.9% ）, cycle fecundity （16. 6% vs. 16. 3% ）, or luteal phase hormone profiles were observed between the groups receiving and not receiving LA.

关 键 词：宫内人工受精 黄体期 人绒毛膜促性腺激素(hCG) 卵巢过度刺激 人绝经期促性腺激素 醋酸 黄体生成素(LH) 雌二醇(E2) 妇女 控制 

分 类 号：R321-33[医药卫生—人体解剖和组织胚胎学] R979.21[医药卫生—基础医学]